Checkpoint Therapeutics Inc Share Price

NASDAQ: CKPT

$4.28

+0.04

(+1.06%)

Live

as on May 30, 2025 at 1:29 am IST

$₹

The stock has been delisted from the stock exchange on 29 May 2025

Checkpoint Therapeutics Inc Stock Performance

as on May 30, 2025 at 1:29 am IST

$4.28
Day's Price Range
$4.28
$4.28
52 Week's Low
52 Week's High
$2.06
52-Week Price Range
$4.5
$4.28
51.87%
Downside
5.14%
Upside

Checkpoint Therapeutics Inc share price movements today

Previous Close: $4.23
Open: $4.28
Volume: 8.0K
Day's Low - High: $4.28 - $4.28
52 Week Low - High: $2.06 - $4.5

Checkpoint Therapeutics Inc Historical Returns

1 Month Return: 0 %
3 Month Return: 0 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Checkpoint Therapeutics Inc Stock Fundamentals & Key Indicators

Check Checkpoint Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

EPS (TTM)

Dividend Yield

0.00%

PE Ratio (TTM)

P/B Ratio

PEG Ratio

Return On Equity TTM

0.00%

Checkpoint Therapeutics Inc stock Key Stats

Compare market cap, revenue, PE, and other key metrics of Checkpoint Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Checkpoint Therapeutics Inc	BUY	$-	NA	NA	0.00%

Analyst Recommendation on Checkpoint Therapeutics Inc Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Checkpoint Therapeutics Inc. Average target price of $4.33

Checkpoint Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Checkpoint Therapeutics Inc.

What analysts predicted

1.15%UPSIDE

Target Price

$4.33

Current Price

$4.28

Analyzed by

10 Analysts

Target

$4.33

Checkpoint Therapeutics Inc target price $4.33, a slight upside of 1.15% compared to current price of $4.28. According to 10 analysts rating.

Checkpoint Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Total Revenue	0	0	0	0	0	-	0	-	0	-
Gross Profit	-14	-15	-13	-5	-8	-8	-4	-	12	-
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-25	-2	-16	-5	-19	-10	-6	-9	-28	-11
Net Profit Margin	-34277.03%	-8185.71%	-53293.55%	-18464.52%	-318800.00%	0.00%	-16268.29%	0.00%	70487.80%	0.00%

Checkpoint Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	0	2	1	3	1	1	0	0	0	0
Gross Profit	-10	-17	-17	3	1	1	0	-49	-43	0
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-13	-22	-22	-36	-24	-22	-56	-66	-51	-56
Net Profit Margin	-2354.58%	-873.97%	-1314.61%	-1037.28%	-1438.99%	-2147.90%	-21125.75%	-34851.56%	-50336.89%	-137170.73%

Global Institutional Holdings in Checkpoint Therapeutics Inc

Funds	Holdings
Beryl Capital Management LLC	6.98%
Highbridge Capital Management, LLC	4.4%
The Toronto-Dominion Bank	3.94%
Glazer Capital, LLC	3.64%
Vanguard Group Inc	2.31%

See all

About Checkpoint Therapeutics Inc

Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. The Company is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cutaneous squamous cell carcinoma. The Company is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Its anti-GITR monoclonal antibody, CK-302, is a fully human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.

Organisation	Checkpoint Therapeutics Inc
E-voting on shares	Click here to vote

FAQs

What is Checkpoint Therapeutics Inc share price today?

Checkpoint Therapeutics Inc share price today is $4.28 as on May 30, 2025 at 1:29 am IST. Checkpoint Therapeutics Inc share today touched a day high of $4.28 and a low of $4.28.

What is the 52 week high and 52 week low for Checkpoint Therapeutics Inc share?

Checkpoint Therapeutics Inc share touched a 52 week high of $4.5 on December 2, 2024 and a 52 week low of $2.06 on September 10, 2024. Checkpoint Therapeutics Inc stock price today i.e. May 30, 2025 at 1:29 am IST is trending at $4.28,which is 4.89% down from its 52 week high and 107.77% up from its 52 week low.

How to invest in Checkpoint Therapeutics Inc Stock (CKPT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Checkpoint Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Checkpoint Therapeutics Inc Shares that will get you 0.3505 shares as per Checkpoint Therapeutics Inc share price of $4.28 per share as on May 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Checkpoint Therapeutics Inc Stock (CKPT) from India?

Indian investors can start investing in Checkpoint Therapeutics Inc (CKPT) shares with as little as ₹88.098 or $1 (as of September 11, 2025 at 12:12 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹880.98 in Checkpoint Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on September 11, 2025 at 12:12 am IST). Based on Checkpoint Therapeutics Inc share’s latest price of $4.28 as on May 30, 2025 at 1:29 am IST, you will get 2.3364 shares of Checkpoint Therapeutics Inc. Learn more about fractional shares .